The biomarkers like ICAM-1 and PECAM-1 can be utilized in the detection of these endothelial damages [41] because increased levels of these biomarkers are indicative of chronic inflammation and endothelial dysfunction, which are also the characteristics of the CNS in post-treatment BC patients. This evidence concerns the gene PECAM1 and endothelial dysfunction.